Developer docs
API playgroundTry for free, no card

Search company profiles

Pharma Medico Group

Full company profile

uuid000wxzc

Namestring
Pharma Medico Group
Legal namestring
Pharma Medico ApS
Company typeenum
Private
Founded yearint
1978
Descriptiontext

Pharma Medico Group (legal entity Pharma Medico ApS) is a Danish, family-controlled, privately held pharmaceutical manufacturer founded in 1978 and headquartered in Aarhus, Denmark. It develops and commercialises dermatology therapies derived from 45+ years of research into human proteoglycan function, operating as a self-described top-three global leader in its dermatological categories across 77+ countries with 1,500+ employees.

Its proprietary technology platform — Proteoglycan Replacement Therapy (PRT) — targets Proteoglycan Atrophies as causal pathologies, addressing Proteoglycan Follicular Atrophy in hair growth disorders and Epidermal Dysglycania in age/sun-damaged skin, psoriasis, eczema, and dermatitis. A patented production process underpins proprietary delivery technologies designed to optimise bioavailability and efficacy, and the company reports a portfolio of 3,300+ intellectual property rights supporting these originator therapies. Three core brands anchor the portfolio: Nourkrin (hair growth), Nourella (skin repair and rejuvenation with next-generation retinoids), and Zymbilan (chronic inflammatory skin disease).

The business model is a channel-partnered, multi-tier global distribution play: pharma preparations and raw materials are produced at eight facilities across Scandinavia/Europe, Asia, MENA, and South America; therapies are routed through regional, national, and local representations, blue chip in-licensing and distribution partners, own national distribution entities, and major retail chains, reaching 500,000+ commercial locations worldwide. Customers are primarily healthcare professionals (dermatologists, trichologists) who prescribe the brands as monotherapy or adjunctive treatments, and downstream consumers access them via retail. The research pipeline targets further dermatological indications including skin cancer, herpes, acne, and pigmentation disorders.

Short descriptiontext

Pharma Medico Group is a Danish, family-controlled pharmaceutical manufacturer founded in 1978, developing Proteoglycan Replacement Therapies for dermatological disorders including hair loss, skin ageing, and inflammatory skin disease, sold across 77+ countries under the Nourkrin, Nourella, and Zymbilan brands.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersAarhus, Denmark
HQ citystring
Aarhus
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dermatological pharmaceuticals, proteoglycan replacement therapy, hair growth treatments, skin repair therapies, pharmaceutical manufacturing
Industry2 codes
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Dermatological Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Preparations and Raw Materials
TypeOne Time License
Description

Manufacturer of pharmaceutical preparations and raw materials implemented in products. Global leader within dermatological categories with therapies including Nourkrin (hair growth), Nourella (skin repair), and Zymbilan (psoriasis/eczema/dermatitis).

pharmamedico.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Nourkrin
Description

Hair Growth Disorders - Addresses Proteoglycan Follicular Atrophy. Preferred by dermatologists, trichologists, and health care professionals as monotherapy and in combination with other products.

pharmamedico.com
+2 more records
Core offering1 text field

Pharma Medico Group is a manufacturer of pharmaceutical preparations and raw materials, specializing in dermatological therapies developed through Applied Proteoglycan Research. The company develops and markets biologically active originator therapies addressing Proteoglycan Atrophies, with core brands Nourkrin (hair growth disorders), Nourella (age and sun damaged skin), and Zymbilan (psoriasis, eczema, and dermatitis). Production is conducted at eight facilities across Scandinavia, Europe, Asia, MENA, and South America, with therapies distributed in over 500,000 commercial locations across 77+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Available in over 500,000 commercial locations globally
+3 more records
Product overview1 text field

Pharma Medico Group offers a portfolio of three distinct dermatological therapy brands developed through Applied Proteoglycan Research. The core offerings include Nourkrin for hair growth disorders (addressing Proteoglycan Follicular Atrophy), Nourella for skin repair and rejuvenation (Proteoglycan Replacement Therapy with next-generation retinoids), and Zymbilan for chronic inflammatory skin conditions (addressing Epidermal Dysglycania). These therapies are biologically active, enable long-term use, and work to restore biological balance and normal biological function rather than merely addressing symptoms. The company operates globally with products available in over 500,000 commercial locations worldwide.

Product and service1 record
1Nourkrin
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Blue Chip In-licensing and Distribution Partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Local blue chip in-licensing and distribution partners working closely with regional and national representations. These strategic partnerships extend global reach and complement the Group's own national distribution entities. The ethos underscores the importance of geographical representation in countries where the company does business.

pharmamedico.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on immuno-inflammatory and dermatological diseases. It represents an emerging, science-driven dermatology peer targeting similar inflammatory skin conditions as Zymbilan.

TypeEmerging player
Description

Hims & Hers is a direct-to-consumer telehealth and wellness platform offering hair-loss and skincare treatments. It is an emerging competitor in the hair-growth category where Nourkrin operates, though it relies on a digital-first model rather than prescriber channels.

TypeBroad incumbent
Description

Almirall is a European-headquartered pharmaceutical company focused on dermatology, offering prescription products for skin diseases. It overlaps with Zymbilan in psoriasis, eczema, and dermatitis, and competes in the same prescriber-driven dermatology market.

TypeEmerging player
Description

Vyome Therapeutics is an emerging clinical-stage dermatology company developing therapies for inflammatory skin diseases and skin cancers. Its pipeline orientation toward dermatology indications is comparable to Pharma Medico's research pipeline expansion areas.

TypeDirect peer
Description

Viviscal is a hair-growth supplement brand positioned similarly to Nourkrin in addressing thinning hair through nutritional intervention. It is one of the most directly comparable hair-loss brands in the same consumer and professional channels.

6Bayer Consumer Health
TypeBroad incumbent
Description

Bayer's consumer health division markets dermatology and self-care brands globally. As a broad incumbent, Bayer competes in adjacent dermatology and hair-care categories with substantially larger marketing and distribution budgets than Pharma Medico.

TypeDirect peer
Description

Galderma is a global dermatology-focused pharmaceutical company with branded prescription and aesthetic products. It is a direct competitor to Pharma Medico in dermatology categories, with overlapping prescriber base (dermatologists) and similar go-to-market through healthcare professionals.

TypeDirect peer
Description

Pierre Fabre's dermatology division develops and markets pharmaceutical and dermo-cosmetic products for skin and hair disorders globally. It competes with Pharma Medico's Nourella and Nourkrin brands across prescription dermatology and dermo-cosmetic channels.

TypeBroad incumbent
Description

La Roche-Posay, part of L'Oréal's dermatological beauty division, is a major global dermo-cosmetic brand for sensitive, aging, and inflammatory skin conditions. It overlaps with Nourella and Zymbilan in skincare for eczema, dermatitis, and sun-damaged skin, though it operates at much larger scale.

TypeDirect peer
Description

Church & Dwight owns Viviscal, a leading hair-growth supplement brand, putting it in direct competition with Pharma Medico's Nourkrin. Both target the same hair loss and thinning category through similar retail and professional channels.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharma Medico Group

Dermatological Pharmaceuticalspharmamedico.com

Pharma Medico Group is a Danish, family-controlled pharmaceutical manufacturer founded in 1978, developing Proteoglycan Replacement Therapies for dermatological disorders including hair loss, skin ageing, and inflammatory skin disease, sold across 77+ countries under the Nourkrin, Nourella, and Zymbilan brands.

What Pharma Medico Group does

Pharma Medico Group (legal entity Pharma Medico ApS) is a Danish, family-controlled, privately held pharmaceutical manufacturer founded in 1978 and headquartered in Aarhus, Denmark. It develops and commercialises dermatology therapies derived from 45+ years of research into human proteoglycan function, operating as a self-described top-three global leader in its dermatological categories across 77+ countries with 1,500+ employees.

Its proprietary technology platform — Proteoglycan Replacement Therapy (PRT) — targets Proteoglycan Atrophies as causal pathologies, addressing Proteoglycan Follicular Atrophy in hair growth disorders and Epidermal Dysglycania in age/sun-damaged skin, psoriasis, eczema, and dermatitis. A patented production process underpins proprietary delivery technologies designed to optimise bioavailability and efficacy, and the company reports a portfolio of 3,300+ intellectual property rights supporting these originator therapies. Three core brands anchor the portfolio: Nourkrin (hair growth), Nourella (skin repair and rejuvenation with next-generation retinoids), and Zymbilan (chronic inflammatory skin disease).

The business model is a channel-partnered, multi-tier global distribution play: pharma preparations and raw materials are produced at eight facilities across Scandinavia/Europe, Asia, MENA, and South America; therapies are routed through regional, national, and local representations, blue chip in-licensing and distribution partners, own national distribution entities, and major retail chains, reaching 500,000+ commercial locations worldwide. Customers are primarily healthcare professionals (dermatologists, trichologists) who prescribe the brands as monotherapy or adjunctive treatments, and downstream consumers access them via retail. The research pipeline targets further dermatological indications including skin cancer, herpes, acne, and pigmentation disorders.

Pharma Medico Group firmographics

Firmographics
Name
Pharma Medico Group
Legal name
Pharma Medico ApS
Website
https://pharmamedico.com
Company type
Private
Founded year
1978
Operating status
Operating
Short description
Pharma Medico Group is a Danish, family-controlled pharmaceutical manufacturer founded in 1978, developing Proteoglycan Replacement Therapies for dermatological disorders including hair loss, skin ageing, and inflammatory skin disease, sold across 77+ countries under the Nourkrin, Nourella, and Zymbilan brands.
Ownership category
akta.pro rank

Pharma Medico Group industry classification

Industry
Product category
Dermatological Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals

Keywords

  • Dermatological pharmaceuticals
  • Proteoglycan replacement therapy
  • Hair growth treatments
  • Skin repair therapies
  • Pharmaceutical manufacturing

Where Pharma Medico Group is headquartered

Location

Headquarters

HQ city
Aarhus
HQ country
Denmark
HQ region
Europe

Offices4 records

Markets served

Pharma Medico Group business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Preparations and Raw Materials: Manufacturer of pharmaceutical preparations and raw materials implemented in products. Global leader within dermatological categories with therapies including Nourkrin (hair growth), Nourella (skin repair), and Zymbilan (psoriasis/eczema/dermatitis).

Go-to-market motion1 record

Distribution channels4 records

Marketing channels1 record

Pharma Medico Group product offering

Product offering

Core offering

Pharma Medico Group is a manufacturer of pharmaceutical preparations and raw materials, specializing in dermatological therapies developed through Applied Proteoglycan Research. The company develops and markets biologically active originator therapies addressing Proteoglycan Atrophies, with core brands Nourkrin (hair growth disorders), Nourella (age and sun damaged skin), and Zymbilan (psoriasis, eczema, and dermatitis). Production is conducted at eight facilities across Scandinavia, Europe, Asia, MENA, and South America, with therapies distributed in over 500,000 commercial locations across 77+ countries.

Product overview

Pharma Medico Group offers a portfolio of three distinct dermatological therapy brands developed through Applied Proteoglycan Research. The core offerings include Nourkrin for hair growth disorders (addressing Proteoglycan Follicular Atrophy), Nourella for skin repair and rejuvenation (Proteoglycan Replacement Therapy with next-generation retinoids), and Zymbilan for chronic inflammatory skin conditions (addressing Epidermal Dysglycania). These therapies are biologically active, enable long-term use, and work to restore biological balance and normal biological function rather than merely addressing symptoms. The company operates globally with products available in over 500,000 commercial locations worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • Nourkrin: Hair Growth Disorders - Addresses Proteoglycan Follicular Atrophy. Preferred by dermatologists, trichologists, and health care professionals as monotherapy and in combination with other products.
  • Nourella
  • Zymbilan

Products and services

  • Nourkrin

Quantifiable outcome

  • Available in over 500,000 commercial locations globally
  • +3 more outcomes

Companies that use Pharma Medico Group

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Pharma Medico Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pharma Medico Group partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Blue Chip In-licensing and Distribution PartnerscoreChannel Partner/ Reseller/ DistributorLocal blue chip in-licensing and distribution partners working closely with regional and national representations. These strategic partnerships extend global reach and complement the Group's own national distribution entities. The ethos underscores the importance of geographical representation in countries where the company does business.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Pharma Medico Group competitors and assessment

Company assessment

Emerging players

  • Aclaris Therapeutics: Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on immuno-inflammatory and dermatological diseases. It represents an emerging, science-driven dermatology peer targeting similar inflammatory skin conditions as Zymbilan.
  • Hims & Hers Health: Hims & Hers is a direct-to-consumer telehealth and wellness platform offering hair-loss and skincare treatments. It is an emerging competitor in the hair-growth category where Nourkrin operates, though it relies on a digital-first model rather than prescriber channels.
  • Vyome Therapeutics: Vyome Therapeutics is an emerging clinical-stage dermatology company developing therapies for inflammatory skin diseases and skin cancers. Its pipeline orientation toward dermatology indications is comparable to Pharma Medico's research pipeline expansion areas.

Broad incumbents

  • Almirall: Almirall is a European-headquartered pharmaceutical company focused on dermatology, offering prescription products for skin diseases. It overlaps with Zymbilan in psoriasis, eczema, and dermatitis, and competes in the same prescriber-driven dermatology market.
  • Bayer Consumer Health: Bayer's consumer health division markets dermatology and self-care brands globally. As a broad incumbent, Bayer competes in adjacent dermatology and hair-care categories with substantially larger marketing and distribution budgets than Pharma Medico.
  • La Roche-Posay (L'Oréal Dermatological Beauty): La Roche-Posay, part of L'Oréal's dermatological beauty division, is a major global dermo-cosmetic brand for sensitive, aging, and inflammatory skin conditions. It overlaps with Nourella and Zymbilan in skincare for eczema, dermatitis, and sun-damaged skin, though it operates at much larger scale.

Direct peers

  • Viviscal (brand) / Church & Dwight competitor Nutraceutical Wellness: Viviscal is a hair-growth supplement brand positioned similarly to Nourkrin in addressing thinning hair through nutritional intervention. It is one of the most directly comparable hair-loss brands in the same consumer and professional channels.
  • Galderma: Galderma is a global dermatology-focused pharmaceutical company with branded prescription and aesthetic products. It is a direct competitor to Pharma Medico in dermatology categories, with overlapping prescriber base (dermatologists) and similar go-to-market through healthcare professionals.
  • Pierre Fabre Dermatologie: Pierre Fabre's dermatology division develops and markets pharmaceutical and dermo-cosmetic products for skin and hair disorders globally. It competes with Pharma Medico's Nourella and Nourkrin brands across prescription dermatology and dermo-cosmetic channels.
  • Church & Dwight (Viviscal): Church & Dwight owns Viviscal, a leading hair-growth supplement brand, putting it in direct competition with Pharma Medico's Nourkrin. Both target the same hair loss and thinning category through similar retail and professional channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Pharma Medico Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharma Medico Group leadership team

Management profile

Number of profiles

Profiles1 record

Pharma Medico Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharma Medico Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma Medico Group

What does Pharma Medico Group do?

Pharma Medico Group is a manufacturer of pharmaceutical preparations and raw materials, specializing in dermatological therapies developed through Applied Proteoglycan Research. The company develops and markets biologically active originator therapies addressing Proteoglycan Atrophies, with core brands Nourkrin (hair growth disorders), Nourella (age and sun damaged skin), and Zymbilan (psoriasis, eczema, and dermatitis). Production is conducted at eight facilities across Scandinavia, Europe, Asia, MENA, and South America, with therapies distributed in over 500,000 commercial locations across 77+ countries.

Is Pharma Medico Group a public or private company?

Pharma Medico Group is a private company. It is classified as family owned and is currently operating.

When was Pharma Medico Group founded?

Pharma Medico Group was founded in 1978.

Where is Pharma Medico Group based?

Pharma Medico Group is headquartered in Aarhus, Denmark, in the Europe region.

How does Pharma Medico Group make money?

One revenue line is on record: pharmaceutical Preparations and Raw Materials.

Who are Pharma Medico Group's main competitors?

Emerging players on record are Aclaris Therapeutics, Hims & Hers Health and Vyome Therapeutics. Broad incumbents are Almirall, Bayer Consumer Health and La Roche-Posay (L'Oréal Dermatological Beauty). Direct peers are Viviscal (brand) / Church & Dwight competitor Nutraceutical Wellness, Galderma, Pierre Fabre Dermatologie and Church & Dwight (Viviscal).

Does Pharma Medico Group have an API?

No public API is recorded for Pharma Medico Group.

What industry is Pharma Medico Group in?

Pharma Medico Group's product category is Dermatological Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales